WallStreetZenWallStreetZen

NASDAQ: ETON
Eton Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ETON

Based on 4 analysts offering 12 month price targets for Eton Pharmaceuticals Inc

Min Forecast
$62.00+11.71%
Avg Forecast
$67.50+21.62%
Max Forecast
$70.00+26.13%

Should I buy or sell ETON stock?

Based on 4 analysts offering ratings for Eton Pharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ETON stock forecasts and price targets.

ETON stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-08-14Find Out Why
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-07-28

1 of 1

Forecast return on equity

Is ETON forecast to generate an efficient return?

Company
264.1%
Industry
60.97%
Market
168.71%
ETON's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ETON forecast to generate an efficient return on assets?

Company
106.24%
Industry
23.53%
ETON is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ETON earnings per share forecast

What is ETON's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$1.20+156.09%
Avg 2 year Forecast
$2.23+373.66%
Avg 3 year Forecast
$3.26+593.94%
ETON's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ETON revenue forecast

What is ETON's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$145.7M+37.98%
Avg 2 year Forecast
$217.8M+106.23%
Avg 3 year Forecast
$291.1M+175.69%
ETON's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ETON earnings growth forecast

How is ETON forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
90.7%
Industry
18.35%
Market
31.22%
ETON's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ETON's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ETON's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ETON revenue growth forecast

How is ETON forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
40.22%
Industry
10.63%
Market
13.78%
ETON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ETON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ETON vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
ETON$55.50$67.50+21.62%Strong Buy
ANIP$76.14$104.50+37.25%Buy
PAHC$34.56$44.00+27.31%Hold
PRGO$13.56N/AN/A
HROW$33.08$66.20+100.12%Strong Buy
View Top Pharmaceutical Stocks

Eton Pharmaceuticals Stock Forecast FAQ

Is Eton Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ETON) stock is to Strong Buy ETON stock.

Out of 4 analysts, 2 (50%) are recommending ETON as a Strong Buy, 2 (50%) are recommending ETON as a Buy, 0 (0%) are recommending ETON as a Hold, 0 (0%) are recommending ETON as a Sell, and 0 (0%) are recommending ETON as a Strong Sell.

If you're new to stock investing, here's how to buy Eton Pharmaceuticals stock.

What is ETON's earnings growth forecast for 2026-2028?

(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual earnings growth rate of 90.7% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 18.35%, and it is also forecast to beat the US market's average forecast earnings growth rate of 31.22%.

Eton Pharmaceuticals's earnings in 2026 is $12,688,000.On average, 6 Wall Street analysts forecast ETON's earnings for 2026 to be $34,402,661, with the lowest ETON earnings forecast at $26,610,899, and the highest ETON earnings forecast at $45,618,683. On average, 6 Wall Street analysts forecast ETON's earnings for 2027 to be $63,631,775, with the lowest ETON earnings forecast at $46,499,044, and the highest ETON earnings forecast at $89,736,752.

In 2028, ETON is forecast to generate $93,223,895 in earnings, with the lowest earnings forecast at $73,390,057 and the highest earnings forecast at $111,045,479.

What is ETON's revenue growth forecast for 2026-2028?

(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 40.22% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Eton Pharmaceuticals's revenue in 2026 is $105,595,000.On average, 6 Wall Street analysts forecast ETON's revenue for 2026 to be $4,164,562,770, with the lowest ETON revenue forecast at $3,364,520,821, and the highest ETON revenue forecast at $4,571,014,949. On average, 6 Wall Street analysts forecast ETON's revenue for 2027 to be $6,224,549,309, with the lowest ETON revenue forecast at $4,971,178,839, and the highest ETON revenue forecast at $7,102,051,553.

In 2028, ETON is forecast to generate $8,320,836,430 in revenue, with the lowest revenue forecast at $6,629,572,332 and the highest revenue forecast at $10,670,941,790.

What is ETON's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ETON) forecast ROA is 106.24%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 23.53%.

What is ETON's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ETON price target, the average ETON price target is $67.50, with the highest ETON stock price forecast at $70.00 and the lowest ETON stock price forecast at $62.00.

On average, Wall Street analysts predict that Eton Pharmaceuticals's share price could reach $67.50 by Aug 14, 2027. The average Eton Pharmaceuticals stock price prediction forecasts a potential upside of 21.62% from the current ETON share price of $55.50.

What is ETON's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ETON) Eton Pharmaceuticals's current Earnings Per Share (EPS) is $0.47. On average, analysts forecast that ETON's EPS will be $1.20 for 2026, with the lowest EPS forecast at $0.93, and the highest EPS forecast at $1.60. On average, analysts forecast that ETON's EPS will be $2.23 for 2027, with the lowest EPS forecast at $1.63, and the highest EPS forecast at $3.14. In 2028, ETON's EPS is forecast to hit $3.26 (min: $2.57, max: $3.89).

What is ETON's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ETON) forecast ROE is 264.1%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.